European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24BMY&src=ctag” target=”_blank”gt;$BMYlt;/agt; lt;a href=”https://twitter.com/hashtag/ALL?src=hash” target=”_blank”gt;#ALLlt;/agt;–Bristol-Myers Squibb Company (NYSE: BMY) today announced that

error: Content is protected !!